Identification of BCL family members as modulators of regorafenib efficacy in experimental glioma (EANO 2025) - Oct 12, 2025 - Abstract #JS04.7.A; Pres time: Oct 17, 2025; 03:50 PM - 04:00 PM; Location: Forum Hall; "RNA sequencing revealed regorafenib-dependent modulation of the Bcl-2 downstream target chemokine receptor 1 (CCR1). We utilized a functional genomics-based target discovery approach with subsequent multi-level validation to identify modulators of regorafenib efficacy. Our findings reveal actionable targets and support the rationale for combinatorial treatment strategies, particularly co-inhibition of Bcl-2 family proteins. These results provide a strong biological rationale for clinical evaluation of regorafenib in combination with navitoclax."
Clinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • ARAF • BCL2 • BCL2L1 • FOXC1 • ITGB3
|
|
L. A. Haeusser1,2; H. Becker1,3; L. Kuhlburger1,4,5; M. Zago1,6,7; B. Walter1; F. Tsiami1; S. Erdmann1,2; J. Trampert1; S. Surender1; A. Stahl8; M. Templin8; E. Wegner8; T. Schmidt8; C. Schmees8; N. Casadei9; L. Sevenich1,2,10; M. Claassen6,11,7; S. Nahnsen10,4,12; S. Beck1,2; D. J. Merk1,12; G. Tabatabai1,2,12
|